

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

## Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant dependent manner

Roanne Keeton<sup>1,2,\*</sup>, Simone I. Richardson<sup>3,4,\*</sup>, Thandeka Moyo-Gwete<sup>3,4,\*</sup>, Tandile Hermanus<sup>3,4,\*</sup>, Marius B. Tincho<sup>1,2</sup>, Ntombi Benede<sup>1,2</sup>, Nelia P. Manamela<sup>3,4</sup> Richard Baguma<sup>1</sup>, Zanele Makhado<sup>3,4</sup>, Amkele Ngomti<sup>1,2</sup>, Thopisang Motlou<sup>3,4</sup>, Mathilda Mennen<sup>5</sup>, Lionel Chinhoyi<sup>5</sup>, Sango Skelem<sup>5</sup>, Hazel Maboreke<sup>1,6</sup>, Deelan Doolabh<sup>1,2</sup>, Arash Iranzadeh<sup>1,2</sup>, Ashley D. Otter<sup>7</sup>, Tim Brooks<sup>7</sup>, Mahdad Noursadeghi<sup>8</sup>, James Moon<sup>9,10</sup>, Alba Grifoni<sup>11</sup>, Daniela Weiskopf<sup>11</sup>, Alessandro Sette<sup>11,12</sup>, Jonathan Blackburn<sup>1,6</sup>, Nei-Yuan Hsiao<sup>2,13</sup>, Carolyn Williamson<sup>1,2,14</sup>, Catherine Riou<sup>1,2,14</sup>, Ameena Goga<sup>15</sup>, Nigel Garrett<sup>16,17</sup>, Linda-Gail Bekker<sup>1,18</sup>, Glenda Gray<sup>15</sup>, Ntobeko A. B. Ntusi<sup>1,5,19,#</sup>, Penny L. Moore<sup>3,4,#</sup>, Wendy A. Burgers<sup>1,2,14,20,#</sup>

### Affiliations

<sup>1</sup>Institute of Infectious Disease and Molecular Medicine; University of Cape Town, Cape Town, South Africa

<sup>2</sup>Division of Medical Virology, Department of Pathology; University of Cape Town, Cape Town, South Africa

<sup>3</sup>National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa

<sup>4</sup>MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa

<sup>5</sup>Department of Medicine, University of Cape Town and Groote Schuur Hospital, South Africa

<sup>6</sup>Division of Chemical and Systems Biology, Department of Integrative Biomedical Sciences, University of Cape Town, Cape Town, South Africa

<sup>7</sup>National Infection Service, Public Health England, Porton Down, UK

<sup>8</sup>Division of Infection and Immunity, University College London, London, UK

<sup>9</sup>Institute of Cardiovascular Sciences, University College London, London, UK

<sup>10</sup>Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK

<sup>11</sup>Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA

<sup>12</sup>Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, California, USA

<sup>13</sup>NHLS Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa

<sup>14</sup>Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Cape Town, South Africa

<sup>15</sup>South African Medical Research Council, Cape Town, South Africa.

<sup>16</sup>Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.

<sup>17</sup>Discipline of Public Health Medicine, University of KwaZulu-Natal, Durban, South Africa.

<sup>18</sup>Desmond Tutu HIV Centre, Cape Town, South Africa.

<sup>19</sup>Hatter Institute for Cardiovascular Research in Africa, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

<sup>20</sup>Lead contact

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 1 \*Equal contribution
- 2 #Equal contribution; Correspondence: [wendy.burgers@uct.ac.za](mailto:wendy.burgers@uct.ac.za) (W.A.B), [pennym@nicd.ac.za](mailto:pennym@nicd.ac.za)
- 3 (P.L.M.) [ntobeko.ntusi@uct.ac.za](mailto:ntobeko.ntusi@uct.ac.za) (N.A.B.N.)

## 1 **Summary**

2 The Johnson and Johnson Ad26.COVS single dose vaccine represents an attractive option  
3 for COVID-19 vaccination in resource limited countries. We examined the effect of prior  
4 infection with different SARS-CoV-2 variants on Ad26.COVS immunogenicity. We  
5 compared participants who were SARS-CoV-2 naïve with those either infected with the  
6 ancestral D614G virus, or infected in the second wave when Beta predominated. Prior infection  
7 significantly boosted spike binding antibodies, antibody-dependent cellular cytotoxicity and  
8 neutralizing antibodies against D614G, Beta and Delta, however neutralization cross-reactivity  
9 varied by wave. Robust CD4 and CD8 T cell responses were induced after vaccination,  
10 regardless of prior infection. T cell recognition of variants was largely preserved, apart from  
11 some reduction in CD8 recognition of Delta. Thus, Ad26.COVS vaccination following  
12 infection may result in enhanced protection against COVID-19. The impact of the infecting  
13 variant on neutralization breadth after vaccination has implications for the design of second-  
14 generation vaccines based on variants of concern.

15 (150 words)

16

## 17 **Introduction**

18 The Johnson and Johnson Ad26.COVS vaccine is a single dose adenovirus 26 vectored  
19 vaccine expressing the SARS-CoV-2 Wuhan-1 stabilized spike. A phase 3 clinical trial of  
20 Ad26.COVS on three continents demonstrated 66% efficacy against moderate disease and  
21 85% protection against severe disease 28 days after vaccination (Sadoff et al., 2021). Moreover,  
22 the South African arm of the trial showed similar levels of efficacy despite the emergence of  
23 the neutralization resistant SARS-CoV-2 Beta variant. Vaccination with Ad26.COVS  
24 triggers neutralizing responses that gradually increase in magnitude and breadth, as well as  
25 potent Fc effector functions and T cell activity, both of which retain activity against variants of  
26 concern (VOC) (Moore et al., 2021; Barouch et al., 2021; Stephenson et al., 2021; Alter et al.,  
27 2021).

28

29 Prior infection boosts titers of binding and neutralizing antibodies elicited by mRNA vaccines  
30 (Manisty et al., 2021; Saadat et al., 2021; Stamatatos et al., 2021; Vanshylla et al., 2021; Wang  
31 et al., 2021b). These increased titers conferred the ability to neutralize SARS-CoV-2 VOCs,  
32 illustrating that only one dose of these vaccines may be sufficient to protect previously infected  
33 individuals. Similarly, a single dose of the BNT162b2 vaccine boosted antibody-dependent  
34 cellular cytotoxicity (ADCC) in previously infected individuals, and T cell cross-reactivity was

1 largely retained (Geers et al., 2021; Reynolds et al., 2021; Tauzin et al., 2021). The impact of  
2 prior infection on immune responses elicited by vectored vaccines is less well defined  
3 (Havervall et al., 2021), as is the impact of the duration between infection and vaccination, or  
4 the genotype of the infecting virus.

5

## 6 **Results**

7 South Africa experienced a first wave of infections in mid-2020, dominated by the ancestral  
8 SARS-CoV-2 D614G variant. From November 2020 to February 2021, a second wave of  
9 infections was dominated by the Beta variant (Tegally et al., 2021; Wibmer et al., 2021; Cele  
10 et al., 2021; Wang et al., 2021a). We established an observational study of 400 healthcare  
11 workers (HCWs) with serial sampling since the first wave. We studied 60 HCWs who were  
12 vaccinated in a Phase 3b implementation trial of single dose Ad26.COV2.S vaccine (Takuva  
13 et al., 2021). HCWs were recruited into three groups, namely those never infected with SARS-  
14 CoV-2 (n=20), and those with PCR-confirmed infection during the first wave (n=20) or second  
15 wave (n=20) (**Figure 1A** and **Supplemental Table S1**). The Beta variant accounted for >90%  
16 of infections in the Western Cape in the second wave (**Figure 1A**), making it likely that this  
17 variant was responsible for infections in the latter group. Indeed, whole genome sequencing of  
18 8/20 second wave participants confirmed infection with Beta. Serological profiles were  
19 generated for each participant by measuring nucleocapsid and spike antibodies since July 2020  
20 (3-8 monthly visits) (**Supplemental Figure S1A-C**). These data confirmed the absence of  
21 infection (or re-infection), and the timing of first or second wave infection. We identified one  
22 potential vaccine breakthrough infection and one suspected re-infection, both excluded from  
23 subsequent analyses.

24

25 Peripheral blood mononuclear cells (PBMC) and plasma were collected prior to vaccination  
26 (median 22 days, IQR 14-29) and approximately one month after vaccination (median 29 days,  
27 IQR 28-34). We tested pre- and post-vaccination plasma for IgG binding antibodies to the  
28 ancestral D614G spike. Binding antibodies elicited by vaccination in the absence of infection  
29 (geometric mean titer [GMT]: 0.22) were comparable with those in both infected groups prior  
30 to vaccination (GMT: 0.28 and 0.32 for first and second wave, respectively). However,  
31 vaccination in HCWs with prior infection in both waves resulted in binding responses being  
32 boosted three fold, to a GMT of 0.87 or 0.9 for the first and second waves, respectively (**Figure**  
33 **1B**). In all HCWs, regardless of prior infection, spike-specific binding antibodies were cross-

1 reactive, with no significant difference in binding between the D614G and Beta spike (**Figure**  
2 **1C**).

3

4 Using a SARS-CoV-2 pseudovirus assay with the D614G spike, we tested neutralizing  
5 antibodies elicited by vaccination alone. Consistent with previous studies (Moore et al., 2021),  
6 we saw low titers post-vaccination in the infection naïve group (GMT: 74). In both groups with  
7 prior infection, we observed a significant boost in neutralization after vaccination against  
8 D614G and Beta (**Figure 2A, Supplemental Figure S2A**). For first wave HCWs, titers were  
9 boosted 13-fold from a GMT of 210 to 2,798 (**Figure 2A**). Second wave HCWs were boosted  
10 12-fold from a GMT of 99 to 1,157. To determine cross-reactivity of neutralizing antibodies,  
11 we compared neutralization of D614G with Beta and Delta. For antibodies induced by  
12 vaccination alone, all participants showed significantly lower titers against Beta (85% showing  
13 no neutralization, GMT: 28) and Delta (78% showing no neutralization, GMT: 29). In both  
14 groups of previously infected HCWs we saw cross-neutralization of Beta and Delta, but the  
15 degree of cross-reactivity varied by wave of infection (**Figure 2B and C**). For HCWs infected  
16 in the first wave, while neutralization of Beta and Delta was maintained, titers were  
17 significantly lower for both VOCs (a reduction in GMT from 2,798 to 606 and 443,  
18 respectively, compared to D614G). In contrast, plasma from those infected in the second wave  
19 with Beta showed no significant difference in neutralization of D614G (GMT: 1157) but 6-fold  
20 lower neutralization of Delta (GMT: 200,  $p < 0.001$ ) (**Figure 2B and C**). Overall, prior infection  
21 followed by vaccination triggered high titer neutralizing antibodies able to neutralize VOCs.  
22 However, the pattern of neutralization varied by wave, suggesting that the neutralizing  
23 antibody repertoire was shaped by the genotype of the infecting variant.

24

25 To assess the impact of prior infection on Fc effector responses to vectored vaccines is  
26 unknown. We measured the ability of plasma antibodies to crosslink FcγRIIIa (CD16)  
27 expressing cells and cell surface D614G, Beta or Delta spikes on target cells, as a surrogate for  
28 ADCC. In previously infected individuals, post-vaccination responses following both waves  
29 were significantly higher against D614G, Beta and Delta (**Figure 3A, Supplemental Figure**  
30 **S2B**), closely mirroring the fold increases of spike binding titers (**Figure 1B**). However,  
31 responses to D614G elicited by vaccination alone (GMT: 39) were similar to those elicited by  
32 infection (GMT: 86 for wave 1 and 54 for wave 2) (**Figure 3A, Supplemental Figure S2B**).  
33 ADCC assays performed using the Beta and Delta variants showed no significant loss in

1 activity compared to D614G in the vaccine-only group (**Figure 3B**) or in individuals with prior  
2 infection (**Figure 3B and C**), demonstrating cross-reactive ADCC responses to VOCs.

3 We examined the effect of prior SARS-CoV-2 infection on vaccine T cell responses. We  
4 measured intracellular cytokine production (IFN- $\gamma$ , TNF- $\alpha$  and IL-2) in response to peptides  
5 covering the Wuhan-1 spike (**Supplemental Figure S3A**). Vaccination induced spike-specific  
6 CD4 and CD8 T cell responses in all groups (**Figure 4A and B**). Infection-naïve participants  
7 or those infected in wave 1 had significantly higher CD4 T cell responses after vaccination  
8 (median: 0.051 and 0.064, respectively). The wave 2 group had pre-existing responses that  
9 were significantly higher than the first wave baseline infection responses, and mounted a more  
10 modest response to vaccination, with similar medians (0.132% and 0.147%, p=ns). CD8  
11 responses were present in fewer individuals prior to vaccination (15 and 32%, vs. 85 and 100%  
12 for CD4 responses in first and second wave groups, respectively), and did not differ  
13 significantly between the groups (**Figure 4B, Supplemental Figure S3B**). Median CD4 T cell  
14 frequencies from pre- to post-vaccination decreased with higher magnitude of pre-existing  
15 responses, with a 5.7-fold change in the infection-naïve group, 1.5-fold in the first wave group  
16 and 1.1-fold in the second wave group. For CD8 responses, the fold-increase was similar for  
17 the three groups (**Figure 4C**). A greater proportion of individuals mounted a CD4 response  
18 compared to a CD8 response (**Figure 4C**). Polyfunctional profiles of vaccine responses  
19 demonstrated that CD4 T cells had the capacity to produce multiple cytokines simultaneously,  
20 while CD8 T cells produced predominantly IFN- $\gamma$  alone (**Supplemental Figure S3C**), with no  
21 significant difference in the profiles after vaccination for those who were infection naïve  
22 compared to those with prior infection.

23 Finally, we assessed whether T cells induced by vaccination recognized Beta and Delta. We  
24 tested spike peptides corresponding to the viral sequences of the ancestral strain, Beta or Delta  
25 in 24 vaccinees. CD4 T cell recognition of Beta or Delta was fully preserved compared to the  
26 ancestral strain (**Figure 4D**). Spike-specific CD8 T cells (in 15/24 participants) cross-  
27 recognised Beta spike in 14/15 responders. In contrast, the median magnitude of the cytokine  
28 response was significantly lower against Delta compared to Beta (p=0.041), and 8/15 (53%) of  
29 CD8 responders had a two-fold or greater reduction in the response to Delta, including five  
30 with complete loss of recognition (**Figure 4D**). Overall, these results demonstrate that robust  
31 CD4 and CD8 T cell responses are generated after vaccination, regardless of prior infection.

1 Vaccine T cell cross-recognition of variants is largely preserved, with the exception of a  
2 reduced ability for CD8 recognition of Delta in some vaccinees.

3

#### 4 **Discussion**

5 Several mRNA vaccines have demonstrated a boosting effect of prior infection (Manisty et al.,  
6 2021; Reynolds et al., 2021; Saadat et al., 2021; Stamatatos et al., 2021; Wang et al., 2021b).  
7 However, whether this is true of viral vectors, including the single dose Johnson and Johnson  
8 vaccine is unclear. We show that infection prior to vaccination with Ad26.COVS.2.S  
9 significantly boosts the magnitude and cross-reactivity of binding antibodies, neutralizing  
10 antibodies and Fc effector function. T cell responses were robustly generated even in the  
11 absence of prior infection and were preserved against Beta. These data have particular  
12 significance in countries like South Africa, where SARS-CoV-2 seropositivity is 20-40%  
13 (Mutevedzi et al., 2021; Hsiao et al., 2020; Sykes et al., 2021). Thus, prior infection may  
14 enhance the protective efficacy of this vaccine, which is frequently used in resource-limited  
15 settings.

16

17 Neutralization breadth was shaped by the variant responsible for infection. Prior exposure to  
18 D614G resulted in reduced titers against both Beta and Delta, consistent with previous studies  
19 (Liu et al., 2021). However, while Beta infection resulted in the preserved neutralization of  
20 D614G, we, like others (Liu et al., 2021), noted significant loss of activity against Delta.  
21 Therefore, while all participants were exposed to the same vaccine, the genotype of the  
22 infecting virus determined the specificity of the responses, prior to vaccine boosting. These  
23 findings have important implications for vaccine design as the sequence of VOC spikes in  
24 second generation vaccines may impact the repertoire of vaccine-induced antibodies.

25

26 Fc effector functions are important in vaccine-elicited protection against many viruses  
27 (Richardson and Moore, 2021). Reduced SARS-CoV-2 severity/mortality correlates with Fc  
28 effector activity (Zohar et al., 2020) and monoclonal antibodies may require Fc function for  
29 optimal protection (Winkler et al., 2021; Schafer et al., 2020). We show that Ad26.COVS.2  
30 vaccination in SARS-CoV-2 naïve HCWs elicits significant ADCC responses, consistent with  
31 previous data (Stephenson et al., 2021). In addition, prior infection significantly enhanced  
32 vaccine-elicited ADCC responses, independent of time post-infection, as for the BNT162b2

1 vaccine (Geers et al., 2021; Tauzin et al., 2021). Finally, unlike neutralizing antibodies, ADCC  
2 activity through vaccination alone, or boosted by prior infection, was cross-reactive for Beta  
3 and Delta. This is consistent with previous findings, and suggests that ADCC-mediating  
4 antibodies target regions of the spike beyond the major neutralization epitopes (Alter et al.,  
5 2021).

6  
7 SARS-CoV-2-specific T cells play a key role in modulating COVID-19 disease severity  
8 (Rydyznski Moderbacher et al., 2020) and provide protective immunity in the context of low  
9 antibody titers (McMahan et al., 2020). We show that robust spike-specific CD4 and CD8  
10 memory T cell responses were induced by AD26.COVS2 vaccination, consistent with Alter et  
11 al (2021). The magnitude of vaccine-induced T cell responses was similar to convalescent  
12 responses. The effect of prior infection was distinct from the antibody response, with CD4  
13 responses in the infection naïve group induced to a similar magnitude as the first wave group,  
14 with existing CD4 T cells only moderately boosted, if at all in the second wave group. There  
15 was an increase in the magnitude and proportion of CD8 responses to spike induced *de novo*  
16 after vaccination, compared to infection, similar for the three study groups. Four participants  
17 in the infection naïve group displayed spike-specific CD8 T cells prior to vaccination, as  
18 described elsewhere, likely through exposure to endemic human coronaviruses (Braun et al.,  
19 2020; Grifoni et al, 2020; Mateus et al., 2020). Of note, most CD8 responses declined after  
20 vaccination, suggesting a lack of cognate cross-reactivity.

21  
22 Vaccination induced T cells that largely cross-recognized peptides based on Beta and Delta  
23 spike, suggesting that most vaccinees target conserved epitopes in spike, as previously  
24 described (Reynolds et al., 2021; Riou et al., 2021b; Gallagher et al., 2021; Geers et al, 2021;  
25 Tarke et al., 2021). However, a third of vaccinees showed reduced CD8 recognition of Delta,  
26 which harbours the L452R mutation that confers resistance to HLA-A\*24:02 recognition  
27 (Motozono et al., 2021). Thus, reduced CD8 recognition of Delta may be attributed to the HLA  
28 repertoire of individuals.

29  
30 Overall, we show a dramatic effect of recent or distant infection on the magnitude and breadth  
31 of neutralizing responses and ADCC. Ad26.COVS2 vaccination alone drives continued  
32 maturation of B cell responses, conferring enhanced neutralization of variants, and durability  
33 (Barouch et al., 2021). Whether prior infection will enhance maturation of neutralizing  
34 antibodies and extend durability still further is unknown. T cell responses, though more



1 modestly impacted by prior infection, were robust and largely cross-reactive. This suggests that  
2 an infection ‘prime’ boosts Ad26.COVS immunogenicity, and in areas of high  
3 seroprevalence, may positively impact the effectiveness of this single dose vaccine. Most  
4 significantly, we show for the first time that breadth of neutralization after vaccination is  
5 dictated by the infecting variant, with important implications for adapted vaccines based on  
6 VOCs.

## 8 **Limitations of the Study**

9 This study focused on variant-specific responses post-vaccination, and we did not fully assess  
10 neutralizing breadth prior to vaccination. However, several studies have now characterised the  
11 neutralizing activity against VOCs, including Delta which now dominates globally, and show  
12 approximately four- to six-fold reduced sensitivity to convalescent plasma, compared to  
13 D614G (Edara et al., 2021; Liu et al, 2021; Planas et al., 2021). Furthermore, whether vectored  
14 vaccines predominantly elicit or boost pre-existing RBD responses, like mRNA vaccines  
15 (Stamatatos et al., 2021), remains to be defined. Finally, further analyses to identify the HLA  
16 alleles associated with reduced CD8 T cell cross-reactivity to Delta, and confirmation of the  
17 mutation(s) that are responsible for epitope loss, would shed light on the significance of cellular  
18 immune evasion by Delta.

## 21 **Acknowledgements**

22 We thank the study participants, and the clinical staff and personnel at Groote Schuur Hospital,  
23 Cape Town for their dedication. We thank F. Ayres, D. Mhlanga, B. Oosthuysen and B.  
24 Lambson for production of protein and pseudoviruses. The parental soluble spike was provided  
25 by J. McLellan. The parental pseudovirus plasmids were kindly provided by Drs E. Landais  
26 and D. Sok. We thank the Variant consortium of South African scientists. The graphical  
27 abstract was created with BioRender.com. This research was supported by the South African  
28 Medical Research Council with funds received from the South African Department of Science  
29 and Innovation (DSI), including grants 96825, SHIPNCD 76756 and DST/CON 0250/2012.  
30 This work was supported by the Poliomyelitis Research Foundation (21/65) and the Wellcome  
31 Centre for Infectious Diseases Research in Africa (CIDRI-Africa), which is supported by core  
32 funding from the Wellcome Trust (203135/Z/16/Z and 222754). Funding support was received  
33 from NIH NIAID with the SARS-CoV-2 Assessment of Viral Evolution program and contract  
34 no. 75N9301900065 to A.S. and D.W. P.L.M. and S.I.R. are supported by the South African

1 Research Chairs Initiative of DSI and the National Research Foundation (NRF; No 98341).  
2 S.I.R. is a L’Oreal/UNESCO Women in Science South Africa Young Talents awardee. W.A.B.  
3 and C.R. are supported by the EDCTP2 programme of the European Union’s Horizon 2020  
4 programme (TMA2017SF-1951-TB-SPEC and TMA2016SF-1535-CaTCH-22). N.A.B.N  
5 acknowledges funding from the SA-MRC, MRC UK, NRF and the Lily and Ernst Hausmann  
6 Trust. M.N. is supported by the Wellcome Trust (207511/Z/17/Z) and by NIHR Biomedical  
7 Research Funding to University College London Hospitals. For the purposes of open access,  
8 the authors have applied a CC BY public copyright license to any author-accepted version  
9 arising from this submission.

10

11

## 12 **Author contributions**

13 W.A.B, P.L.M. and N.A.B.N. designed the study. W.A.B and P.L.M. analyzed the data and  
14 wrote the manuscript. R.K., S.I.R. and T.M.G. generated and analyzed the data and wrote the  
15 manuscript. S.I.R., T.M.G., T.H., N.P.M., Z.M. and T.M. performed antibody assays. R.K.,  
16 M.B.T., N.B., R.B. and A.N. performed T cell assays. M.M., S.S. and L.R.C. managed the  
17 HCW cohort and contributed clinical samples. A.O. and T.B. characterized the serological  
18 profiles. N.Y.H. contributed samples and A.G., D.W. and A.S. provided variant peptide pools.  
19 D.D., A.I. and C.W. performed viral sequencing. H.M. and J.B. contributed to cohort  
20 characterization. C.R. contributed to data analysis. A.G., N.G., L.G.B. and G.G. established  
21 and led the Sisonke vaccine study. N.A.B.N., J.M. and M.N. established and led the HCW  
22 cohort. All authors reviewed and edited the manuscript.

23

24

## 25 **Competing interests**

26 A.S. is a consultant for Gritstone, Flow Pharma, CellCarta, Arcturus, Oxford Immunotech  
27 and Avalia. All of the other authors declare no competing interests. LJI has filed for patent  
28 protection for various aspects of vaccine design and identification of specific epitopes.

29

30

31

32

33

34

## 1 **Figure Legends**

2

3 **Figure 1. Spike-specific antibody responses in Ad26.COVS2.S-vaccinated healthcare**  
4 **workers. A.** Study design showing three groups (left panel), either with no prior infection,  
5 infection in the first wave (May-August 2020) and infection in the second wave (November  
6 2020-January 2021). Samples were taken pre-vaccination and 1 month after vaccination.  
7 SARS-CoV-2 epidemiological dynamics in the Western Cape (South Africa) are shown (top  
8 right panel). Prevalence of SARS-CoV-2 lineages on the left y-axis. The ancestral strain  
9 (D614G) is depicted in blue and Beta in red. The number of COVID-19 cases is represented  
10 on the right y-axis. The bars on top of the graph indicate the periods when participants were  
11 infected in the first and second waves. Vertical dotted lines indicate when vaccination occurred.  
12 Characteristics of participants in the three groups (bottom right panel). Sex, age (median and  
13 IQR) and days since PCR-confirmed infection. **B.** Plasma samples from participants with no  
14 prior infection (green, n=19), first wave infection (blue, n=20) or second wave infection (red,  
15 n=19) were tested for binding to D614G spike protein pre- and post-vaccination (OD<sub>450nm</sub>). **C.**  
16 Cross-reactivity of vaccine-induced antibody responses to D614G and Beta spike. The colored  
17 lines below the graph correspond with the key. The threshold for positivity is indicated by a  
18 dotted line. Horizontal bars indicate GMT, with values shown. Statistical analyses were  
19 performed using the Mann-Whitney test between groups, and the Wilcoxon test for pre- and  
20 post-vaccine time points or D614G compared to Beta responses. \*\*\* denotes p<0.001, ns =  
21 non-significant.

22

23 **Figure 2. Neutralizing antibody responses to Ad26.COVS2.S vaccination. A.** Neutralization  
24 of the SARS-CoV-2 D614G pseudovirus by plasma pre- and post-vaccination from participants  
25 with no prior infection (green, n=19) and those infected in the first (blue, n=20) and second  
26 waves (red, n=19). Neutralization is reflected as an ID<sub>50</sub> titer. The threshold for positivity is  
27 indicated by a dotted line **B.** Cross-reactive neutralization post-vaccination against D614G,  
28 Beta and Delta. Pie charts show the proportion of vaccine non-responders (NR; grey), knock-  
29 out of neutralization of Beta or Delta (KO; black), titer of 20-400 (orange), or >400 (red). **C.**  
30 Fold change of post-vaccination D614G neutralization titers relative to Beta or Delta. The  
31 horizontal bars indicate GMT, with values indicated. Statistical analyses were performed using  
32 the Friedman test between groups, and the Wilcoxon test for paired analyses. \* denotes p<0.05,  
33 \*\*\* p<0.001, ns, non-significant.

34

1 **Figure 3. Antibody-dependent cellular cytotoxicity (ADCC) responses to Ad26.COV2.S**  
2 **vaccination. A.** ADCC activity represented as relative light units (RLU). **B.** Cross-reactive  
3 ADCC activity 28 days post-vaccination against D614G, Beta and Delta. Pie charts show the  
4 proportion of vaccine non-responders (NR; grey), knock-out of Beta/Delta neutralization (KO;  
5 black), or detectable ADCC activity (41-150, orange and >150, red). **C.** Fold-change of post-  
6 vaccination D614G ADCC levels relative to the Beta/Delta variants. The horizontal bars  
7 indicate GMT, with values indicated. Statistical analyses were performed using the Friedman  
8 test between groups, and the Wilcoxon test for pre- and post-vaccine time points or D614G  
9 compared to Beta/Delta responses. \* denotes  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , ns, non-  
10 significant.

11  
12  
13 **Figure 4. T cell responses to Ad26.COV2.S vaccination. A.** Frequency of total cytokine-  
14 producing spike-specific CD4 T cells, and **B.** CD8 T cells, in those with no prior infection  
15 (green, n=19), infection in the first wave (blue, n=20), and infection in the second wave (red,  
16 n=19), in PBMC stimulated with peptides based on Wuhan spike. **C.** Median fold-change of  
17 CD4 and CD8 T cell frequencies after vaccination in responders. Error bars indicate IQR. Pie  
18 charts show responders (black) and non-responders (grey), with the percentage of responders  
19 indicated. **D.** Cross-reactivity of T cell responses post-vaccination (n=24) after peptide  
20 stimulation with spike from the ancestral strain, Beta or Delta is shown. Horizontal bars  
21 indicate medians. The dotted line indicates the threshold for positivity and values are  
22 background-subtracted. Statistical analyses were performed using the Wilcoxon test. \* denotes  
23  $p < 0.05$ , \*\*  $p < 0.01$ , ns = non-significant.

## 24 **STAR METHODS**

## 25 **RESOURCE AVAILABILITY**

### 26 **Lead contact**

27 Further information and requests for resources and reagents should be directed to and will be  
28 fulfilled by the lead contact, Wendy Burgers ([wendy.burgers@uct.ac.za](mailto:wendy.burgers@uct.ac.za)).

### 29 **Materials availability**

30 Materials will be made available by request to Wendy Burgers ([wendy.burgers@uct.ac.za](mailto:wendy.burgers@uct.ac.za)).

31  
32  
33  
34

## 1 **Data and code availability**

2 The published article includes all data generated or analyzed during this study, and summarized  
3 in the accompanying tables, figures and supplemental materials.

## 5 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

### 7 **Human Subjects**

8 Participants were recruited from a longitudinal study of healthcare workers (HCW; n=400)  
9 enrolled from Groote Schuur Hospital (Cape Town, Western Cape, South Africa). HCW in this  
10 cohort were recruited between July 2020 and January 2021, and vaccination with single dose  
11 Johnson and Johnson Ad26.COVS.2 in the Sisonke Phase 3b trial took place between 17  
12 February and 26 March 2021. Sixty participants were selected for inclusion in this study, based  
13 on the availability of PBMC and plasma prior to vaccination and approximately one month  
14 after vaccination, and who fell into one of three groups: (1) No evidence of previous SARS-  
15 CoV-2 infection by diagnostic PCR test or serial serology; (2) infection during the ‘first wave’  
16 of the pandemic in South Africa, prior to 1 September 2020, with known date of laboratory  
17 (PCR)-confirmed SARS-CoV-2 infection; and (3) infection during the ‘second wave’, with  
18 known date of laboratory (PCR)-confirmed SARS-CoV-2 infection between 1 November 2020  
19 and 31 January 2021. Full demographic and clinical characteristics of participants are  
20 summarized in **Supplemental Table S1**. The study was approved by the University of Cape  
21 Town Human Research Ethics Committee (HREC 190/2020 and 209/2020) and the University  
22 of the Witwatersrand Human Research Ethics Committee (Medical) (no M210429). Written  
23 informed consent was obtained from all participants.

### 25 **Cell Lines**

26 Human embryo kidney HEK293T cells were cultured at 37°C, 5% CO<sub>2</sub>, in DMEM containing  
27 10% heat-inactivated fetal bovine serum (Gibco BRL Life Technologies) and supplemented  
28 with 50 µg/ml gentamicin (Sigma). Cells were disrupted at confluence with 0.25% trypsin in 1  
29 mM EDTA (Sigma) every 48–72 hours. HEK293T-ACE2 cells were maintained in the same  
30 way as HEK293T cells but were supplemented with 3 µg/ml puromycin for selection of stably  
31 transduced cells. Jurkat-Lucia™ NFAT-CD16 cells were maintained in IMDM media with  
32 10% heat-inactivated fetal bovine serum (Gibco, Gaithersburg, MD), 1% Penicillin  
33 Streptomycin (Gibco, Gaithersburg, MD) and 10 µg/ml of Blasticidin and 100 µg/ml of Zeocin  
34 was added to the growth medium every other passage.

1

## 2 **METHOD DETAILS**

3

### 4 **SARS-CoV-2 spike WGS and phylogenetic analysis**

5 Whole genome sequencing (WGS) of SARS-CoV-2 was performed using nasopharyngeal  
6 swabs obtained from 19 of the hospitalized patients recruited during the second COVID-19  
7 wave. Sequencing was performed as previously published (Moyo-Gwete et al., 2021). Briefly,  
8 cDNA was synthesized from RNA extracted from the nasopharyngeal swabs using the  
9 Superscript IV First Strand synthesis system (Life Technologies, Carlsbad, CA) and random  
10 hexamer primers. Whole genome amplification was then performed by multiplex PCR using  
11 the ARTIC V3 protocol (<https://www.protocols.io/view/ncov-2019-sequencing-protocol-v3-locost-bh42j8ye>). PCR products were purified with AMPure XP magnetic beads (Beckman  
12 Coulter, CA) and quantified using the Qubit dsDNA High Sensitivity assay on the Qubit 3.0  
13 instrument (Life Technologies Carlsbad, CA). The Illumina® DNA Prep kit was used to  
14 prepare indexed paired end libraries of genomic DNA. Sequencing libraries were normalized  
15 to 4 nM, pooled, and denatured with 0.2 N sodium hydroxide. Libraries were sequenced on the  
16 Illumina MiSeq instrument (Illumina, San Diego, CA, USA). The quality control checks on  
17 raw sequence data and the genome assembly were performed using Genome Detective 1.132  
18 (<https://www.genomedetective.com>) and the Coronavirus Typing Tool (Cleemput et al., 2020).  
19 The initial assembly obtained from Genome Detective was polished by aligning mapped reads  
20 to the references and filtering out low-quality mutations using bcftools 1.7-2 mpileup method.  
21 Mutations were confirmed visually with bam files using Geneious software (Biomatters Ltd,  
22 New Zealand). Phylogenetic clade classification of the genomes in this study consisted of  
23 analyzing them against a global reference dataset using a custom pipeline based on a local  
24 version of NextStrain (<https://github.com/nextstrain/ncov>) (Hadfield et al., 2018).  
25

26

### 27 **Roche serology**

28 Serial serum samples were analysed from longitudinal study visits from enrolment to post-  
29 vaccination (3-8 time points per participant) at Public Health England, Porton Down. The  
30 Elecsys anti-SARS-CoV-2 Spike and the Elecsys anti-SARS-CoV-2 electrochemiluminescent  
31 immunoassays were performed (Roche Diagnostics, GmbH), which enable detection of total  
32 antibodies against the SARS-CoV-2 spike (S) receptor binding domain (RBD) and  
33 nucleocapsid (N) proteins, respectively. Samples were analysed on a Cobas e801 instrument

1 and a result  $\geq 0.8$  U/mL was considered positive in the S assay, and  $\geq 1.0$  U/mL positive in the  
2 N assay, according to the manufacturer's instructions.

3

#### 4 **Isolation of PBMC**

5 Blood was collected in heparin tubes and processed within 3 hours of collection. Peripheral  
6 blood mononuclear cells (PBMC) were isolated by density gradient sedimentation using Ficoll-  
7 Paque (Amersham Biosciences, Little Chalfont, UK) as per the manufacturer's instructions and  
8 cryopreserved in freezing media consisting of heat-inactivated fetal bovine serum (FBS,  
9 ThermoFisher Scientific) containing 10% DMSO and stored in liquid nitrogen until use.

10

#### 11 **SARS-CoV-2 antigens**

12 For serology assays, SARS-CoV-2 original and beta variant spike proteins were expressed in  
13 Human Embryonic Kidney (HEK) 293F suspension cells by transfecting the cells with the  
14 spike plasmid. After incubating for six days at 37°C, 70% humidity and 10% CO<sub>2</sub>, proteins  
15 were first purified using a nickel resin followed by size-exclusion chromatography. Relevant  
16 fractions were collected and frozen at -80 °C until use.

17 For T cell assays, we used peptides covering the full length SARS-CoV-2 spike protein,  
18 by combining two commercially available peptide pools of 15mer sequences with 11 amino  
19 acids (aa) overlap (PepTivator®, Miltenyi Biotech, Bergisch Gladbach, Germany). These  
20 peptides are based on the Wuhan-1 strain and cover the N-terminal S1 domain of SARS-CoV-  
21 2 from aa 1 to 692, as well as the majority of the C-terminal S2 domain. Pools were resuspended  
22 in distilled water at a concentration of 50 µg/mL and used at a final concentration of 1 µg/mL.  
23 To determine T cell responses to SARS-CoV-2 variants, peptides were synthesized that  
24 spanned the entire SARS-CoV-2 spike protein and corresponded to the ancestral Wuhan  
25 sequence (GenBank: MN908947) or the Beta (B.1.351; GISAID: EPI\_ISL\_736932,  
26 EPI\_ISL\_736944, EPI\_ISL\_736971, EPI\_ISL\_736966, EPI\_ISL\_736973, EPI\_ISL\_825104,  
27 EPI\_ISL\_825120, EPI\_ISL\_825131), as previously reported (Tarke et al., 2021) or to the Delta  
28 SARS-CoV-2 variants (B.1.617.2; GISAID: EPI\_ISL\_2020950). Peptides were 15-mers  
29 overlapping by 10 amino acids and were synthesized as crude material (TC Peptide Lab, San  
30 Diego, CA). All peptides were individually resuspended in dimethyl sulfoxide (DMSO) at a  
31 concentration of 10–20 mg/mL. Megapools for each antigen were created by pooling aliquots  
32 of these individual peptides in the respective SARS-CoV-2 spike sequences, followed by  
33 sequential lyophilization steps, and resuspension in DMSO at 1 mg/mL. Pools were used at a

1 final concentration of 1 µg/mL with an equimolar DMSO concentration in the non-stimulated  
2 control.

3

#### 4 **SARS-CoV-2 Spike ELISA**

5 Two µg/ml of spike protein were used to coat 96-well, high-binding plates and incubated  
6 overnight at 4°C. The plates were incubated in a blocking buffer consisting of 5% skimmed  
7 milk powder, 0.05% Tween 20, 1x PBS. Plasma samples were diluted to 1:100 starting dilution  
8 in a blocking buffer and added to the plates. Secondary antibody was diluted to 1:3000 in  
9 blocking buffer and added to the plates followed by TMB substrate (Thermofisher Scientific).  
10 Upon stopping the reaction with 1 M H<sub>2</sub>SO<sub>4</sub>, absorbance was measured at a 450nm wavelength.  
11 In all instances, mAbs CR3022 and BD23 were used as positive controls and palivizumab was  
12 used as a negative control. All values were normalized with the CR3022 mAb.

13

#### 14 **Pseudovirus neutralization assay**

15 SARS-CoV-2 pseudotyped lentiviruses were prepared by co-transfecting the HEK 293T cell  
16 line with either the SARS-CoV-2 ancestral variant spike (D614G), the Beta spike (L18F,  
17 D80A, D215G, K417N, E484K, N501Y, D614G, A701V, 242-244 del) or the Delta spike  
18 (T19R, R158G L452R, T478K, D614G, P681R, D950N, 156-157 del) plasmids in conjunction  
19 with a firefly luciferase encoding lentivirus backbone plasmid. For the neutralization assay,  
20 heat-inactivated plasma samples from vaccine recipients were incubated with the SARS- CoV-  
21 2 pseudotyped virus for 1 hour at 37°C, 5% CO<sub>2</sub>. Subsequently, 1x10<sup>4</sup> HEK 293T cells  
22 engineered to over-express ACE-2 were added and incubated at 37°C, 5% CO<sub>2</sub> for 72 hours  
23 upon which the luminescence of the luciferase gene was measured. CB6 was used as a positive  
24 control.

25

#### 26 **ADCC assay**

27 The ability of plasma antibodies to cross-link FcγRIIIa (CD16) and spike expressing cells was  
28 measured as a proxy for antibody-dependent cellular cytotoxicity (ADCC). HEK293T cells  
29 were transfected with 5µg of SARS-CoV-2 original variant spike (D614G), Beta or Delta spike  
30 plasmids using PEI-MAX 40,000 (Polysciences) and incubated for 2 days at 37°C. Expression  
31 of spike was confirmed by binding of CR3022 and P2B-2F6 and their detection by anti-IgG  
32 APC staining measured by flow cytometry. Subsequently, 1x10<sup>5</sup> spike transfected cells per  
33 well were incubated with heat inactivated plasma (1:100 final dilution) or control mAbs (final  
34 concentration of 100 µg/ml) in RPMI 1640 media supplemented with 10% FBS 1% Pen/Strep



1 (Gibco, Gaithersburg, MD) for 1 hour at 37°C. Jurkat-Lucia™ NFAT-CD16 cells (Invivogen)  
2 (2x10<sup>5</sup> cells/well) were added and incubated for 24 hours at 37°C, 5% CO<sub>2</sub>. Twenty µl of  
3 supernatant was then transferred to a white 96-well plate with 50 µl of reconstituted QUANTI-  
4 Luc secreted luciferase and read immediately on a Victor 3 luminometer with 1s integration  
5 time. Relative light units (RLU) of a no antibody control were subtracted as background.  
6 Palivizumab was used as a negative control, while CR3022 was used as a positive control, and  
7 P2B-2F6 to differentiate the Beta from the D614G variant. To induce the transgene 1x cell  
8 stimulation cocktail (Thermofisher Scientific, Oslo, Norway) and 2 µg/ml ionomycin in R10  
9 was added as a positive control.

10

### 11 **Cell stimulation and flow cytometry staining**

12 Cryopreserved PBMC were thawed, washed and rested in RPMI 1640 containing 10% heat-  
13 inactivated FCS for 4 hours prior to stimulation. PBMC were seeded in a 96-well V-bottom  
14 plate at ~2 x 10<sup>6</sup> PBMC per well and stimulated with SARS-CoV-2 spike peptide pools: full  
15 spike pool (Miltenyi), and ancestral and beta mutated S1 and S2 pools (1 µg/mL). All  
16 stimulations were performed in the presence of Brefeldin A (10 µg/mL, Sigma-Aldrich, St  
17 Louis, MO, USA) and co-stimulatory antibodies against CD28 (clone 28.2) and CD49d (clone  
18 L25) (1 µg/mL each; BD Biosciences, San Jose, CA, USA). As a negative control, PBMC were  
19 incubated with co-stimulatory antibodies, Brefeldin A and an equimolar amount of DMSO.

20 After 16 hours of stimulation, cells were washed, stained with LIVE/DEAD™ Fixable  
21 VIVID Stain (Invitrogen, Carlsbad, CA, USA) and subsequently surface stained with the  
22 following antibodies: CD14 Pac Blue (TuK4, Invitrogen Thermofisher Scientific), CD19 Pac  
23 Blue (SJ25-C1, Invitrogen Thermofisher Scientific), CD4 PERCP-Cy5.5 (L200, BD  
24 Biosciences, San Jose, CA, USA), CD8 BV510 (RPA-8, Biolegend, San Diego, CA, USA),  
25 PD-1 BV711 (EH12.2H7, Biolegend, San Diego, CA, USA), CD27 PE-Cy5 (1A4, Beckman  
26 Coulter), CD45RA BV570 (HI100, Biolegend, San Diego, CA, USA). Cells were then fixed  
27 and permeabilized using a Cytotfix/Cyto perm buffer (BD Biosciences) and stained with CD3  
28 BV650 (OKT3) IFN-g Alexo 700 (B27), TNF BV786 (Mab11) and IL-2 APC (MQ1-17H12)  
29 from Biolegend. Finally, cells were washed and fixed in CellFIX (BD Biosciences). Samples  
30 were acquired on a BD LSR-II flow cytometer and analyzed using FlowJo (v10, FlowJo LLC,  
31 Ashland, OR, USA). A median of 282 848 CD4 events (IQR:216 796 - 355 414) and 153 192  
32 CD8 events (IQR 109 697 - 202 204) were acquired. Cells were gated on singlets, CD14-  
33 CD19-, live lymphocytes and memory cells (excluding naive CD27+ CD45RA+ population).  
34 Results are expressed as the frequency of CD4+ or CD8+ T cells expressing IFN-g, TNF-a or

1 IL-2. Due to high TNF- $\alpha$  backgrounds, cells producing TNF- $\alpha$  alone were excluded from the  
2 analysis. Cytokine responses presented are background subtracted values (from the frequency  
3 of cytokine produced in unstimulated cells), and the threshold for a positive cytokine response  
4 was defined as  $>0.02\%$ .

5

## 6 **QUANTIFICATION AND STATISTICAL ANALYSIS**

7

8 Statistical analyses were performed in Prism (v9; GraphPad Software Inc, San Diego, CA,  
9 USA). Non-parametric tests were used for all comparisons. The Mann-Whitney, Friedman and  
10 Wilcoxon tests were used for unmatched and paired samples, respectively. All correlations  
11 reported are non-parametric Spearman's correlations. *P* values less than 0.05 were considered  
12 statistically significant. Details of analysis performed for each experiment are described in the  
13 figure legends.

14

15

16

## 17 **References**

18

19 Alter, G., Yu, J., Liu, J., Chandrashekar, A., Borducchi, E.N., Tostanoski, L.H., McMahan,  
20 K., Jacob-Dolan, C., Nkolola, J., Stephenson, K.E., et al. (2021). Immunogenicity of  
21 Ad26.COV2.S Against SARS-CoV-2 Variants. *Nature* 9, 1-9.  
22 <http://dx.doi.org/10.1038/s41586-021-03681-2>.

23

24 Anand, S.P., Prevost, J., Nayrac, M., Beaudoin-Bussieres, G., Benlarbi, M., Gasser, R.,  
25 Brassard, N., Laumaea, A., Gong, S.Y., Bourassa, C., et al. (2021). Longitudinal analysis of  
26 humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months  
27 post-symptom onset. *Cell Rep Med* 2. <http://dx.doi.org/10.1016/j.xcrm.2021.100290>.

28

29 Barouch, D.H., Stephenson, K.E., Sadoff, J., Yu, J., Chang, A., Gebre, M., McMahan, K.,  
30 Liu, J., Chandrashekar, A., and Patel, S. (2021). Durable Humoral and Cellular Immune  
31 Responses 8 Months after Ad26.COV2.S Vaccination. *New England Journal of Medicine*.  
32 <http://dx.doi.org/10.1056/NEJMc2108829>.

33

34 Barrett, J.R., Belij-Rammerstorfer, S., Dold, C., Ewer, K.J., Folegatti, P.M., Gilbride, C.,  
35 Halkerston, R., Hill, J., Jenkin, D., Stockdale, L., et al. (2021). Phase 1/2 trial of SARS-CoV-  
36 2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody  
37 responses. *Nat Med* 27, 279-288. <http://dx.doi.org/10.1038/s41591-020-01179-4>.

38

39 Braun, J., Loyal, L., Frentsch, M., Wendisch, D., Georg, P., Kurth, F., Hippenstiel, S.,  
40 Dingeldey, M., Kruse, B., Fauchere, F., et al. (2020). SARS-CoV-2-reactive T cells in  
41 healthy donors and patients with COVID-19. *Nature* 587, 270–274.  
42 <https://dx.doi.org/10.1038/s41586-020-2598-9>.

- 1  
2 Brouwer, P.J., Caniels, T.G., van der Straten, K., Snitselaar, J.L., Aldon, Y., Bangaru, S.,  
3 Torres, J.L., Okba, N.M., Claireaux, M., and Kerster, G. (2020). Potent neutralizing  
4 antibodies from COVID-19 patients define multiple targets of vulnerability. *Science* 369,  
5 643-650. <http://dx.doi.org/10.1126/science.abc5902>.  
6  
7 Cele, S., Gazy, I., Jackson, L., Hwa, S.H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S.,  
8 Wilkinson, E., Naidoo, Y., et al. (2021). Escape of SARS-CoV-2 501Y.V2 from  
9 neutralization by convalescent plasma. *Nature* 593, 142-146.  
10 <http://dx.doi.org/10.1038/s41586-021-03471-w>.  
11  
12 Cleemput, S., Dumon, W., Fonseca, V., Abdool Karim, W., Giovanetti, M., Alcantara, L.C.,  
13 Deforche, K., and De Oliveira, T. (2020). Genome Detective Coronavirus Typing Tool for  
14 rapid identification and characterization of novel coronavirus genomes. *Bioinformatics* 36,  
15 3552-3555. <http://dx.doi.org/10.1093/bioinformatics/btaa145>.  
16  
17 Edara, V.V., Pinsky, B.A., Suthar, M.S., Lai, L., Davis-Gardner, M.E., Floyd, K., Flowers,  
18 M.W., Wrammert, J., Hussaini, L., Ciric, C.R., et al. (2021). Infection and Vaccine-Induced  
19 Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants. *New England*  
20 *Journal of Medicine* 12, 664-666. <http://dx.doi.org/10.1056/nejmc2107799>.  
21  
22 Gallagher, K.M.E., Leick, M.B., Larson, R.C., Berger, T.R., Katsis, K., Yam, J.Y., Brini, G.,  
23 Grauwet, K., Collection, M.C.-., Processing, T., and Maus, M.V. (2021). SARS -CoV-2 T-  
24 cell immunity to variants of concern following vaccination. *bioRxiv*.  
25 <http://dx.doi.org/10.1101/2021.05.03.442455>.  
26  
27 Geers, D., Shamier, M.C., Bogers, S., den Hartog, G., Gommers, L., Nieuwkoop, N.N.,  
28 Schmitz, K.S., Rijsbergen, L.C., van Osch, J.A.T., Dijkhuizen, E., et al. (2021). SARS-CoV-2  
29 variants of concern partially escape humoral but not T-cell responses in COVID-19  
30 convalescent donors and vaccinees. *Sci Immunol* 6.  
31 <http://dx.doi.org/10.1126/sciimmunol.abj1750>.  
32  
33 Grifoni, A., Weiskopf, D., Ramirez, S.I., Mateus, J., Dan, J.M., Moderbacher, C.R.,  
34 Rawlings, S.A., Sutherland, A., Premkumar, L., Jodi, R.S., et al. (2020). Targets of T Cell  
35 Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed  
36 Individuals. *Cell* 181, 1489-1501.e15. <https://dx.doi.org/10.1016/j.cell.2020.05.015>  
37  
38 Hadfield, J., Megill, C., Bell, S.M., Huddleston, J., Potter, B., Callender, C., Sagulenko, P.,  
39 Bedford, T., and Neher, R.A. (2018). Nextstrain: real-time tracking of pathogen evolution.  
40 *Bioinformatics* 34, 4121-4123. <http://dx.doi.org/10.1093/bioinformatics/bty407>.  
41  
42 Havervall, S., Marking, U., Greilert-Norin, N., Ng, H., Salomonsson, A.-C., Hellström, C.,  
43 Pin, E., Blom, K., Mangsbo, S., Phillipson, M., et al. (2021). Antibody Responses After a  
44 Single Dose of ChAdOx1 nCoV-19 Vaccine in Healthcare Workers Previously Infected with  
45 SARS-CoV-2. *medRxiv*. <http://dx.doi.org/10.1101/2021.05.08.21256866>.  
46  
47 Hsiao, M., Davies, M., and Kalk, E. (2020). SARS-CoV-2 seroprevalence in the Cape Town  
48 Metropolitan sub-districts after the peak of infections. *NICD COVID-19 Special Public*  
49 *Health Surveill Bull* 18, 1-9.


- 1 Klingler, J., Lambert, G.S., Itri, V., Liu, S., Bandres, J.C., Enyindah-Asonye, G., Liu, X.,  
2 Oguntuyo, K.Y., Amanat, F., and Lee, B. (2021). SARS-CoV-2 mRNA vaccines induce a  
3 greater array of spike-specific antibody isotypes with more potent complement binding  
4 capacity than natural infection. medRxiv. <http://dx.doi.org/10.1101/2021.05.11.21256972>.  
5
- 6 Lee, W.S., Selva, K.J., Davis, S.K., Wines, B.D., Reynaldi, A., Esterbauer, R., Kelly, H.G.,  
7 Haycroft, E.R., Tan, H.X., Juno, J.A., et al. (2021). Decay of Fc-dependent antibody  
8 functions after mild to moderate COVID-19. *Cell Rep Med* 2, 100296.  
9 <http://dx.doi.org/10.1016/j.xcrm.2021.100296>.  
10
- 11 Liu, C., Ginn, H.M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., Nutalai, R.,  
12 Zhou, D., Mentzer, A.J., Zhao, Y., et al. (2021). Reduced neutralization of SARS-CoV-2 B.  
13 1.617 by vaccine and convalescent serum. *Cell* 184, 1-17.  
14 <http://dx.doi.org/10.1016/j.cell.2021.06.020>.  
15
- 16 Manisty, C., Otter, A.D., Treibel, T.A., McKnight, Á., Altmann, D.M., Brooks, T.,  
17 Noursadeghi, M., Boyton, R.J., Semper, A., and Moon, J.C. (2021). Antibody response to  
18 first BNT162b2 dose in previously SARS-CoV-2-infected individuals. *The Lancet* 397, 1057-  
19 1058. [http://dx.doi.org/10.1016/S0140-6736\(21\)00501-8](http://dx.doi.org/10.1016/S0140-6736(21)00501-8).  
20
- 21 Mateus, J., Grifoni, A., Tarke, A., Sidney, J., Ramirez, S.I., Dan, J.M., Burger, Z.C.,  
22 Rawlings, S.A., Smith, D.M., Phillips, E., et al. (2020). Selective and cross-reactive SARS-  
23 CoV-2 T cell epitopes in unexposed humans. *Science* 370, 89–94.  
24 <https://dx.doi.org/10.1126/science.abd3871>.  
25
- 26 McMahan, K., Yu, J., Mercado, N.B., Loos, C., Tostanoski, L.H., Chandrashekar, A., Liu, J.,  
27 Peter, L., Atyeo, C., Zhu, A., et al. (2021). Correlates of protection against SARS-CoV-2 in  
28 rhesus macaques. *Nature* 590, 630-634. <http://dx.doi.org/10.1038/s41586-020-03041-6>.  
29
- 30 Mercado, N.B., Zahn, R., Wegmann, F., Loos, C., Chandrashekar, A., Yu, J., Liu, J., Peter,  
31 L., McMahan, K., and Tostanoski, L.H. (2020). Single-shot Ad26 vaccine protects against  
32 SARS-CoV-2 in rhesus macaques. *Nature* 586, 583-588. <http://dx.doi.org/10.1038/s41586-020-2607-z>.  
33  
34
- 35 Moore, P., Moyo-Gwete, T., Hermanus, T., Kgagudi, P., Ayres, F., Makhado, Z., Sadoff, J.,  
36 Le Gars, M., van Roey, G., Crowther, C., et al. (2021). Neutralizing antibodies elicited by the  
37 Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B. 1.351),  
38 despite protection against severe disease by this variant. bioRxiv.  
39 <http://dx.doi.org/10.1101/2021.06.09.447722>.  
40
- 41 Motozono, C., Toyoda, M., Zahradnik, J., Saito, A., Nasser, H., Tan, T.S., Ngare, I., Kimura,  
42 I., Uriu, K., Kosugi, Y., et al. (2021). SARS-CoV-2 spike L452R variant evades cellular  
43 immunity and increases infectivity. *Cell Host & Microbe* 29, 1124-1136.e11.  
44 <https://dx.doi.org/10.1016/j.chom.2021.06.006>.  
45
- 46 Moyo-Gwete, T., Madzivhandila, M., Makhado, Z., Ayres, F., Mhlanga, D., Oosthuysen, B.,  
47 Lambson, B.E., Kgagudi, P., Tegally, H., Iranzadeh, A., et al. (2021). Cross-Reactive  
48 Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351). *New*  
49 *England Journal of Medicine*. <http://dx.doi.org/10.1056/NEJMc2104192>.  
50

- 1 Mutevedzi, P.C., Kawonga, M., Kwatra, G., Moultrie, A., Baillie, V.L., Mabhena, N.,  
2 Mathibe, M.N., Rafuma, M.M., Maposa, I., and Abbott, G. (2021). Population Based SARS-  
3 CoV-2 Sero-Epidemiological Survey and Estimated Infection Incidence and Fatality Risk in  
4 Gauteng Province, South Africa. Available at SSRN:  
5 <https://ssrn.com/abstract=3855442>. <http://dx.doi.org/10.2139/ssrn.3855442>.  
6
- 7 Nielsen, S.C., Yang, F., Jackson, K.J., Hoh, R.A., Röltgen, K., Jean, G.H., Stevens, B.A.,  
8 Lee, J.-Y., Rustagi, A., and Rogers, A.J. (2020). Human B cell clonal expansion and  
9 convergent antibody responses to SARS-CoV-2. *Cell Host & Microbe* 28, 516-525. e515.  
10 <http://dx.doi.org/10.1016/j.chom.2020.09.002>.  
11
- 12 Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M.M.,  
13 Planchais, C., Porrot, F., Robillard, N., Puech, J., et al. (2021). Reduced sensitivity of SARS-  
14 CoV-2 variant Delta to antibody neutralization. *Nature* 596, 276–280.  
15 <https://dx.doi.org/10.1038/s41586-021-03777-9>.  
16
- 17 Reynolds, C.J., Pade, C., Gibbons, J.M., Butler, D.K., Otter, A.D., Menacho, K., Fontana, M.,  
18 Smit, A., Sackville-West, J.E., Cutino-Moguel, T., et al. (2021). Prior SARS-CoV-2 infection  
19 rescues B and T cell responses to variants after first vaccine dose. *Science* 372, 1418–1423.  
20 <https://dx.doi.org/10.1126/science.abh1282>.  
21
- 22 Richardson, S.I., and Moore, P.L. (2021). Targeting Fc effector function in vaccine design.  
23 *Expert Opin Ther Targets*, 1-11. <http://dx.doi.org/10.1080/14728222.2021.1907343>.  
24
- 25 Riou, C., du Bruyn, E., Stek, C., Daroowala, R., Goliath, R.T., Abrahams, F., Said-Hartley,  
26 Q., Allwood, B.W., Hsiao, N.Y., Wilkinson, K.A., et al. (2021a). Relationship of SARS-  
27 CoV-2-specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis  
28 coinfection. *J Clin Invest* 131. <http://dx.doi.org/10.1172/JCI149125>.  
29
- 30 Riou, C., Keeton, R., Moyo-Gwete, T., Hermanus, T., Kgagudi, P., Baguma, R., Tegally, H.,  
31 Doolabh, D., Iranzadeh, A., Tyers, L., et al. (2021b). Loss of recognition of SARS-CoV-2  
32 B.1.351 variant spike epitopes but overall preservation of T cell immunity. medRxiv.  
33 <http://dx.doi.org/10.1101/2021.06.03.21258307>.  
34
- 35 Robbiani, D.F., Gaebler, C., Muecksch, F., Lorenzi, J.C., Wang, Z., Cho, A., Agudelo, M.,  
36 Barnes, C.O., Gazumyan, A., and Finkin, S. (2020). Convergent antibody responses to  
37 SARS-CoV-2 in convalescent individuals. *Nature* 584, 437-442.  
38 <http://dx.doi.org/10.1038/s41586-020-2456-9>.  
39
- 40 Rydzynski Moderbacher, C., Ramirez, S.I., Dan, J.M., Grifoni, A., Hastie, K.M., Weiskopf,  
41 D., Belanger, S., Abbott, R.K., Kim, C., Choi, J., et al. (2020). Antigen-Specific Adaptive  
42 Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease  
43 Severity. *Cell* 183, 996-1012 e1019. <http://dx.doi.org/10.1016/j.cell.2020.09.038>.  
44
- 45 Saadat, S., Tehrani, Z.R., Logue, J., Newman, M., Frieman, M.B., Harris, A.D., and Sajadi,  
46 M.M. (2021). Binding and neutralization antibody titers after a single vaccine dose in health  
47 care workers previously infected with SARS-CoV-2. *JAMA* 325, 1467-1469.  
48 <http://dx.doi.org/10.1001/jama.2021.3341>.  
49


- 1 Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert,  
2 P.A., Truyers, C., Fennema, H., and Spiessens, B. (2021). Safety and efficacy of single-dose  
3 Ad26. COV2. S vaccine against Covid-19. *New England Journal of Medicine* 384, 2187-  
4 2201. <http://dx.doi.org/10.1056/NEJMoa2101544>.  
5
- 6 Sattler, A., Angermair, S., Stockmann, H., Heim, K.M., Khadzhynov, D., Treskatsch, S.,  
7 Halleck, F., Kreis, M.E., and Kotsch, K. (2020). SARS-CoV-2-specific T cell responses and  
8 correlations with COVID-19 patient predisposition. *J Clin Invest* 130, 6477-6489.  
9 <http://dx.doi.org/10.1172/JCI140965>.  
10
- 11 Schafer, A., Muecksch, F., Lorenzi, J.C.C., Leist, S.R., Cipolla, M., Bournazos, S., Schmidt,  
12 F., Maison, R.M., Gazumyan, A., Martinez, D.R., et al. (2021). Antibody potency, effector  
13 function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. *J*  
14 *Exp Med* 218. <http://dx.doi.org/10.1084/jem.20201993>.  
15
- 16 Stamatatos, L., Czartoski, J., Wan, Y.H., Homad, L.J., Rubin, V., Glantz, H., Neradilek, M.,  
17 Seydoux, E., Jennewein, M.F., MacCamy, A.J., et al. (2021). mRNA vaccination boosts  
18 cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. *Science*.  
19 <http://dx.doi.org/10.1126/science.abg9175>.  
20
- 21 Stephenson, K.E., Le Gars, M., Sadoff, J., de Groot, A.M., Heerwegh, D., Truyers, C., Atyeo,  
22 C., Loos, C., Chandrashekar, A., and McMahan, K. (2021). Immunogenicity of the Ad26.  
23 COV2. S Vaccine for COVID-19. *JAMA* 325, 1535-1544.  
24 <http://dx.doi.org/10.1001/jama.2021.3645>.  
25
- 26 Sykes, W., Mhlanga, L., Swanevelder, R., Glatt, T.N., Grebe, E., Coleman, C., Pieterse, N.,  
27 Cable, R., Welte, A., and van den Berg, K. (2021). Prevalence of anti-SARS-CoV-2  
28 antibodies among blood donors in Northern Cape, KwaZulu-Natal, Eastern Cape, and Free  
29 State provinces of South Africa in January 2021. *Research Square*.  
30 <http://dx.doi.org/10.21203/rs.3.rs-233375/v1>.  
31
- 32 Takuva, S., Takalani, A., Garrett, N., Goga, A., Peter, J., Louw, V., Opie, J., Jacobson, B.,  
33 Sanne, I., and Gail-Bekker, L. (2021). Thromboembolic Events in the South African Ad26.  
34 COV2. S Vaccine Study. *New England Journal of Medicine* 385, 570-571.  
35 <http://dx.doi.org/10.1056/NEJMc2107920>.  
36
- 37 Tarke, A., Sidney, J., Methot, N., Yu, E.D., Zhang, Y., Dan, J.M., Goodwin, B., Rubiro, P.,  
38 Sutherland, A., Wang, E., et al. (2021). Impact of SARS-CoV-2 variants on the total CD4(+)  
39 and CD8(+) T cell reactivity in infected or vaccinated individuals. *Cell Rep Med*, 100355.  
40 <http://dx.doi.org/10.1016/j.xcrm.2021.100355>.  
41
- 42 Tauzin, A., Nayrac, M., Benlarbi, M., Gong, S.Y., Gasser, R., Beaudoin-Bussieres, G.,  
43 Brassard, N., Laumaea, A., Vezina, D., Prevost, J., et al. (2021). A single dose of the SARS-  
44 CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell  
45 responses. *Cell Host & Microbe* 29, 1137-1150 e1136.  
46 <http://dx.doi.org/10.1016/j.chom.2021.06.001>.  
47
- 48 Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J.,  
49 Doolabh, D., Pillay, S., San, E.J., Msomi, N., et al. (2021). Detection of a SARS-CoV-2

- 1 variant of concern in South Africa. *Nature* 592, 438-443. [http://dx.doi.org/10.1038/s41586-](http://dx.doi.org/10.1038/s41586-021-03402-9)  
2 [021-03402-9](http://dx.doi.org/10.1038/s41586-021-03402-9).  
3
- 4 Vanshylla, K., Di Cristanziano, V., Kleipass, F., Dewald, F., Schommers, P., Giesemann, L.,  
5 Gruell, H., Schlotz, M., Ercanoglu, M.S., and Stumpf, R. (2021). Kinetics and correlates of  
6 the neutralizing antibody response to SARS-CoV-2 infection in humans. *Cell Host &*  
7 *Microbe* 29, 917-929. e914. <http://dx.doi.org/10.1016/j.chom.2021.04.015>.  
8
- 9 Wang, P., Nair, M.S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B.,  
10 Kwong, P.D., et al. (2021a). Antibody resistance of SARS-CoV-2 variants B.1.351 and  
11 B.1.1.7. *Nature* 593, 130-135. <http://dx.doi.org/10.1038/s41586-021-03398-2>.  
12
- 13 Wang, Z., Muecksch, F., Schaefer-Babajew, D., Finkin, S., Viant, C., Gaebler, C., Hoffmann,  
14 H.-H., Barnes, C.O., Cipolla, M., and Ramos, V. (2021b). Naturally enhanced neutralizing  
15 breadth against SARS-CoV-2 one year after infection. *Nature* 595, 1-10.  
16 <http://dx.doi.org/10.1038/s41586-021-03696-9>.  
17
- 18 Wibmer, C.K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B.,  
19 Lambson, B.E., De Oliveira, T., Vermeulen, M., and Van der Berg, K. (2021). SARS-CoV-2  
20 501Y. V2 escapes neutralization by South African COVID-19 donor plasma. *Nature*  
21 *Medicine* 27, 622-625. <http://dx.doi.org/10.1038/s41591-021-01285-x>.  
22
- 23 Winkler, E.S., Gilchuk, P., Yu, J., Bailey, A.L., Chen, R.E., Chong, Z., Zost, S.J., Jang, H.,  
24 Huang, Y., Allen, J.D., et al. (2021). Human neutralizing antibodies against SARS-CoV-2  
25 require intact Fc effector functions for optimal therapeutic protection. *Cell* 184, 1804-1820  
26 e1816. <http://dx.doi.org/10.1016/j.cell.2021.02.026>.  
27
- 28 Zohar, T., Loos, C., Fischinger, S., Atyeo, C., Wang, C., Slein, M.D., Burke, J., Yu, J.,  
29 Feldman, J., and Hauser, B.M. (2020). Compromised humoral functional evolution tracks  
30 with SARS-CoV-2 mortality. *Cell* 183, 1508-1519. e1512.  
31 <http://dx.doi.org/10.1016/j.cell.2020.10.052>.


**A**



**B**



**C**



● No prior infection ● 1<sup>st</sup> wave infection ● 2<sup>nd</sup> wave infection

**Figure 1**






Figure 2




Figure 3




Figure 4.